Acrivon Therapeutics, Inc. 10-Q filing
Filed 2025-11-13 · Report date 2025-09-30 · 2025
Filing metadata
- Accession number
- 0001193125-25-280215
- Form type
- 10-Q
- CIK
- 0001781174
- Primary document
- https://www.sec.gov/Archives/edgar/data/1781174/000119312525280215/acrv-20250930.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Acrivon Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-64.0M | - | - |
| Net Income | $-58.9M | - | - |
| Eps Basic | -1.53 | - | - |
| Eps Diluted | -1.53 | - | - |
| Cash And Equivalents | $35.4M | - | - |
| Total Assets | $145.3M | - | - |
| Total Liabilities | $16.7M | - | - |
| Shareholders Equity | $128.6M | - | - |
| Operating Cash Flow | $-48.4M | - | - |
| Capital Expenditures | $1.4M | - | - |